S. Mealing

发表

An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population.

P. Kanagaratnam, M. Tayebjee, T. Sasikaran, 2024, PharmacoEconomics - open.

Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective

O. Wazni, G. Chierchia, J. Paisey, 2024, Open Heart.

A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation

O. Wazni, G. Chierchia, T. Bromilow, 2024, BMC cardiovascular disorders.

The Cost-Effectiveness of First-Line Cryoablation versus First-Line Antiarrhythmic Drugs in Canadian Patients with Paroxysmal Atrial Fibrillation.

G. Chierchia, Y. Khaykin, T. Bromilow, 2023, The Canadian journal of cardiology.